Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
Personalized treatment of GBM guided by patient-derived organoid

Personalized treatment of GBM guided by patient-derived organoid

Single-cell RNA-seq of IPTO demonstrates that IPTO maintains the human tumor ecosystem
© Haikun Liu, Ph.D.

We also developed a fast, efficient and complex culture system (IPTO: individualized patient-derived tumor organoid) which maintains the cellular diversity and molecular heterogeneity of human brain cancers. Patient derived tumor explant were cultured in iPSC derived cerebral organoid which allow generation of an organoid bank of several hundred of patient tumors. We showed that this model can host all tumors tested the central nervous system, including brain metastasis. Histology, epigenome and scRNA-seq analysis demonstrated that IPTOs model accurately maintain molecular and cellular features of parental tumors. Most importantly, we further demonstrated that the IPTO model predicts patient drug response in a perspective clinical study. The IPTO model represents a major breakthrough in preclinic modeling of human cancers, which provides a clear path toward personalized therapy of brain cancers. Currently efforts in the lab involves using IPTO for patient response prediction and targets discovery and validations.

to top
powered by webEdition CMS